In this volume, we discuss potential pharmacotherapies for children and adolescents with ASD. It also covers the efficacy and safety of ziprasidone for bipolar disorder, outlines the evidence of ketamine for adolescents with treatment-resistant depression, and describes adverse effects associated with increased prolactin levels due to antipsychotics. Finally, it examines the likelihood of children and adolescents developing depression and anxiety when prescribing ADHD medications.
- Provider:Medical Academy, LLC
- Activity Link: https://psychopharmacologyinstitute.com/publication/cap-smart-takes-vol-08-2747?utm_source=PDF+CME+Program&utm_medium=PDF+CME+Program&utm_campaign=PDF+CME+Program
- Start Date: 2023-03-01 06:00:00
- End Date: 2023-03-01 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Yes
- Measured Outcome: Learner Knowledge, Learner Performance
- Provider Ship: Jointly Provided
- Registration: Limited
Subscribe
Login
0 Comments
Oldest